Genetic polymorphisms in CX3CR1 predict HIV-1 disease progression in children independently of CD4+ lymphocyte count and HIV-1 RNA load

Journal of Infectious Diseases

Volumn 191, Issue 11, 2005, Pages 1971-1980

  Singh, Kumud K ^a   Hughes, Michael D ^c   Chen, Jie ^c   Spector, Stephen A ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CX3C CHEMOKINE; CX3CR1 PROTEIN; G PROTEIN COUPLED RECEPTOR; GENE PRODUCT; UNCLASSIFIED DRUG; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, HUMAN; MEMBRANE PROTEIN; VIRUS RECEPTOR; VIRUS RNA;

ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CX3CR1 GENE; DIAGNOSTIC VALUE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; GENETICS; ISOLATION AND PURIFICATION; PATHOPHYSIOLOGY;

CD4 LYMPHOCYTE COUNT; CHILD; DISEASE PROGRESSION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE PROTEINS; POLYMORPHISM, GENETIC; RECEPTORS, CHEMOKINE; RECEPTORS, HIV; RNA, VIRAL; VIRAL LOAD;

EID: 18944377853     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/430091     Document Type: Article

References (27)

1. Michael NL. Host genetic influences on HIV-1 pathogenesis. Curr Opin Immunol 1999; 11:466-74.
2. 3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91:521-30.
3. 3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 1998; 273:23799-804.
4. 3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci USA 2000; 97:8075-80.
5. 3CR1. Science 2000; 287:2274-77.
6. 3CR1 and risk of HIV disease. Science 2000; 290:2031.
7. 3CR1 and the clinical course of HIV infection or virus phenotype evolution. AIDS 2003; 17:759-61.
8. 3CR1 polymorphism. J Acquir Immune Defic Syndr 2001; 26:507-11.
9. 3CR1 genotypes on HIV-1 disease progression. J Acquir Immune Defic Syndr 2003; 32:335-7.
10. 3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 2003; 17:201-8.
11. Foussat A, Bouchet-Delbos L, Berrebi D, et al. Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. Blood 2001; 98:1678-86.
12. Pereira CF, Middel J, Jansen G, Verhoef J, Nottet HS. Enhanced expression of fractalkine in HIV-1 associated dementia. J Neuroimmunol 2001; 115:168-75.
13. 3CL1) and brain inflammation: implications for HIV-1-associated dementia. J Neurovirol 2002; 8:585-98.
14. van der Meer P, Ulrich AM, Gonzalez-Scarano F, Lavi E. Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain: potential mechanisms for HIV dementia. Exp Mol Pathol 2000; 69:192-201.
15. Hatori K, Nagai A, Heisel R, Ryu JK, Kim SU. Fractalkine and fractalkine receptors in human neurons and glial cells. J Neurosci Res 2002; 69:418-26.
16. Singh KK, Barroga CF, Hughes MD, et al. Genetic influence of CCR5, CCR2, and SDF1 variants on HIV-1-related disease progression and neurological impairment in children with symptomatic HIV-1 infection. J Infect Dis 2003; 188:1461-72.
17. Englund JA, Baker CJ, Raskino C, et al. Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. AIDS Clinical Trials Group Protocol 152 Study Team. Pediatr Infect Dis J 1996; 15:1025-36.
18. McKinney RE Jr, Johnson GM, Stanley K, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr 1998; 133:500-8.
19. 3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97:1925-8.
20. + lymphocyte count in HIV-infected infants and children. JAMA 1998; 279:756-61.
21. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
22. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med 1997; 126:939-45.
23. + lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997; 126:929-38.
24. Combadiere B, Faure S, Autran B, Debre P, Combadiere C. The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients. AIDS 2003; 17:1279-90.
25. McDermott DH, Fong AM, Yang Q, et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 2003; 111:1241-50.
26. -/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003; 111:333-40.
27. Segerer S, Hughes E, Hudkins KL, Mack M, Goodpaster T, Alpers CE. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int 2002; 62:488-95.